Trending NewsTrending NewsNASDAQ:CMPX Compass Therapeutics (CMPX) Stock Price, News & Analysis $1.17 -0.07 (-5.65%) Closing price 04:00 PM EasternExtended Trading$1.17 0.00 (0.00%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Compass Therapeutics Stock (NASDAQ:CMPX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Compass Therapeutics alerts:Sign Up Key Stats Today's Range$1.13▼$1.2350-Day Range$1.24▼$2.5352-Week Range$1.13▼$6.88Volume7.68 million shsAverage Volume3.95 million shsMarket Capitalization$210.71 millionP/E RatioN/ADividend YieldN/APrice Target$10.21Consensus RatingModerate Buy Company Overview Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody-based medicines designed to activate and direct the immune system against cancer and other serious diseases. The company’s research is centered on immuno-oncology, with the goal of creating therapies that can stimulate antitumor immune responses and improve outcomes for patients. Compass Therapeutics has developed a pipeline of proprietary antibody therapeutics, including CTX-471, an investigational monoclonal antibody intended to activate CD137, an immune-stimulatory receptor found on certain immune cells. By targeting immune pathways involved in tumor recognition and destruction, the company seeks to develop treatments that may be used alone or in combination with other cancer therapies. The company is headquartered in Cambridge, Massachusetts, and conducts its research and clinical development activities through collaborations with investigators, clinical sites and other biotechnology and pharmaceutical organizations. Compass Therapeutics was founded by scientists with experience in antibody discovery and cancer immunology and is led by a management team focused on advancing its investigational therapies through clinical development.AI Generated. May Contain Errors. Read More Compass Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreCMPX MarketRank™: Compass Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 435th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCompass Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 13 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialCompass Therapeutics has a consensus price target of $10.21, representing about 773.0% upside from its current price of $1.17.Amount of Analyst CoverageCompass Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Compass Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Compass Therapeutics are expected to decrease in the coming year, from ($0.47) to ($0.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Compass Therapeutics is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Compass Therapeutics is -2.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCompass Therapeutics has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Compass Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted27.86% of the float of Compass Therapeutics has been sold short.Short Interest Ratio / Days to CoverCompass Therapeutics has a short interest ratio ("days to cover") of 17.26, which indicates bearish sentiment.Change versus previous monthShort interest in Compass Therapeutics has recently increased by 1.47%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCompass Therapeutics does not currently pay a dividend.Dividend GrowthCompass Therapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment-0.43 News SentimentCompass Therapeutics has a news sentiment score of -0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Compass Therapeutics this week, compared to 4 articles on an average week.Search Interest13 people have searched for CMPX on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.MarketBeat Follows5 people have added Compass Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Compass Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders18.70% of the stock of Compass Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.43% of the stock of Compass Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Compass Therapeutics' insider trading history. Receive CMPX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Compass Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMPX Stock News HeadlinesWedbush Downgrades Compass Therapeutics to Neutral From Outperform, Cuts Price Target to $1 From $541 minutes ago | marketscreener.comMCompass Therapeutics: A Promising, But Shrinking, Window Of Opportunity41 minutes ago | seekingalpha.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.September 23 at 1:00 AM | Decentralized Masters (Ad)Compass Therapeutics Shares Drop After Downgrade From Wedbush41 minutes ago | finance.yahoo.comCompass Therapeutics (CMPX) was downgraded to a Hold Rating at LifeSci Capital41 minutes ago | theglobeandmail.comCompass Therapeutics downgraded at Wedbush as FDA seeks additional trial for lead asset41 minutes ago | msn.comCompass Therapeutics Says FDA Recommends New Tovecimig Trial in Biliary Tract Cancer; Shares FallSeptember 22 at 10:57 PM | finance.yahoo.comCMPX plunge wipes out $104M after FDA demands fresh trial for cancer drug — Wedbush sees another 19% downsideSeptember 22 at 10:57 PM | msn.comSee More Headlines CMPX Stock Analysis - Frequently Asked Questions How have CMPX shares performed this year? Compass Therapeutics' stock was trading at $5.37 at the beginning of the year. Since then, CMPX shares have decreased by 78.2% and is now trading at $1.17. How were Compass Therapeutics' earnings last quarter? Compass Therapeutics, Inc. (NASDAQ:CMPX) announced its earnings results on Thursday, August, 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. When did Compass Therapeutics IPO? Compass Therapeutics (CMPX) raised $50 million in an initial public offering (IPO) on the week of November 16th 2020. The company issued 9,000,000 shares at $5.00-$6.00 per share. Citigroup, Credit Suisse and Stifel acted as the underwriters for the IPO and Raymond James was co-manager. Who are Compass Therapeutics' major shareholders? Top institutional investors of Compass Therapeutics include Montanova Capital LLC (7.83%), BlackRock Inc. (6.26%), Palo Alto Investors LP (3.24%) and Squarepoint Ops LLC (0.56%). Insiders that own company stock include Thomas J Schuetz, Jonathan Anderman and Carl L Gordon. View institutional ownership trends. How do I buy shares of Compass Therapeutics? Shares of CMPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Compass Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Compass Therapeutics investors own include Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Alphabet (GOOG). Company Calendar Last Earnings8/06/2026Today9/23/2026Next Earnings (Estimated)11/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CMPX's financial health is in the Red zone, according to TradeSmith. CMPX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CMPX CIK1738021 Webwww.compasstherapeutics.com Phone617-500-8099FaxN/AEmployees39Year Founded2014Price Target and Rating Average Price Target for Compass Therapeutics$10.21 High Price Target$30.00 Low Price Target$4.00 Potential Upside/Downside+773.0%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.49 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.71% Return on Assets-34.72% Debt Debt-to-Equity RatioN/A Current Ratio11.22 Quick Ratio11.22 Sales & Book Value Annual Sales$850 thousand Price / Sales247.89 Cash FlowN/A Price / Cash FlowN/A Book Value$1.11 per share Price / Book1.05Miscellaneous Outstanding Shares180,090,000Free Float146,412,000Market Cap$210.71 million OptionableNot Optionable Beta0.95 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:CMPX) was last updated on 9/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMPX Stock Alerts